Pharma

Your Article Summary

See Latest Articles

Nanobiotechnology for Hemoglobin-based Blood Substitutes
Critical Care Clinics, 04/10/09

Chang TMS et al. - New generations of this approach include the nanobiotechnological assembly of hemoglobin, catalase, and superoxide dismutase into a soluble nanodimension complex. This is potentially useful in cases of extensive blood loss requiring massive replacement using blood substitutes, resulting in the need for the replacement of platelets and clotting factors. A further step is the preparation of nanodimension artificial red blood cells that contain hemoglobin and all the enzymes present in red blood cells.

Today in Biotechnology...keeping you current

Receive free subspecialty "5-minute updates" via email

Sanofi-aventis and U.S Biotechnology company Alopexx enter into a collaboration agreement for a novel human monoclonal antibody targeting infectious diseases
Sanofi-aventis, 12/11/09

Quality by Design for Biotechnology Products—Part 2
BioPharm, 12/09/09

Amylin Pharmaceuticals to Present at the 2009 Deutsche Bank Biotech Boston Confab
Amylin Pharmaceuticals, 12/09/09

 See all of Biotechnology